LIF Inhibitors
LIF inhibitors constitute a diverse array of compounds that effectively modulate LIF (Leukemia Inhibitory Factor) activity through both direct and indirect mechanisms. The primary target for these inhibitors is the JAK/STAT (Janus kinase/Signal Transducer and Activator of Transcription) signaling pathway, emphasizing their potential to disrupt the intricate regulatory network governing LIF function. Direct inhibitors within this class include AG-490, Pyridone 6, Stattic, Nifuroxazide, Galiellalactone, WP1066, Ruxolitinib, and BMS-911543. AG-490, for instance, specifically inhibits JAK2, leading to the disruption of STAT activation, particularly STAT3. Pyridone 6 selectively targets JAK2, while Stattic and Nifuroxazide act directly on STAT3, interfering with downstream events associated with LIF signaling. The diverse set of direct inhibitors allows for a precise and targeted modulation of LIF activity by disrupting key components of the JAK/STAT pathway.
On the other hand, indirect inhibitors, including Bazedoxifene, NVP-BBT594, Cryptotanshinone, Napabucasin, and NVP-BBT594, exert their effects through pathways intersecting with LIF signaling. Bazedoxifene, functioning as an estrogen receptor modulator, indirectly influences LIF by inhibiting the JAK/STAT3 pathway. NVP-BBT594, acting as a RET and JAK inhibitor, disrupts downstream events associated with LIF signaling. Cryptotanshinone and Napabucasin, both functioning as STAT3 inhibitors, interfere with events downstream of LIF signaling, providing an alternative approach to modulating LIF activity. This chemical class of LIF inhibitors offers a versatile toolkit for researchers aiming to unravel the complexities of LIF biology. The variety of mechanisms employed by these inhibitors to modulate LIF activity allows for a comprehensive exploration of the intricate regulatory networks governing this multifaceted protein. Researchers can leverage the specificities of these inhibitors to gain insights into the nuanced roles of LIF in cellular processes and disease contexts.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490, a JAK2 inhibitor, directly influences LIF by targeting the JAK/STAT signaling pathway. Inhibition of JAK2 by AG-490 disrupts the activation of STATs, particularly STAT3, demonstrating its potential to act as a direct inhibitor of LIF by impeding the JAK/STAT-mediated pathway. | ||||||
JAK Inhibitor I | 457081-03-7 | sc-204021 sc-204021A | 500 µg 1 mg | $156.00 $339.00 | 59 | |
Pyridone 6, a JAK2 inhibitor, directly modulates LIF by inhibiting the JAK/STAT signaling pathway. Through selective inhibition of JAK2, Pyridone 6 interferes with the activation of STAT3, showcasing its potential as a direct inhibitor of LIF by disrupting the JAK/STAT-mediated pathway. | ||||||
Stat3 inhibitor V, stattic | 19983-44-9 | sc-202818 sc-202818A sc-202818B sc-202818C sc-202818D sc-202818E sc-202818F | 25 mg 100 mg 250 mg 500 mg 1 g 2.5 g 5 g | $130.00 $196.00 $274.00 $512.00 $731.00 $1408.00 $2091.00 | 114 | |
Stattic, a STAT3 inhibitor, directly influences LIF by targeting the JAK/STAT3 signaling pathway. Inhibition of STAT3 by Stattic disrupts downstream events associated with LIF signaling, demonstrating its potential to act as a direct inhibitor of LIF by modulating the JAK/STAT3-mediated pathway. | ||||||
Nifuroxazide | 965-52-6 | sc-204128 sc-204128A | 500 mg 5 g | $203.00 $520.00 | 5 | |
Nifuroxazide, a STAT3 inhibitor, directly modulates LIF by affecting the JAK/STAT3 signaling pathway. Inhibition of STAT3 by Nifuroxazide disrupts downstream events associated with LIF signaling, showcasing its potential to act as a direct inhibitor of LIF by interfering with the JAK/STAT3-mediated pathway. | ||||||
Galiellalactone | 133613-71-5 | sc-202165 | 1 mg | $418.00 | 9 | |
Galiellalactone, a STAT3 inhibitor, directly influences LIF by targeting the JAK/STAT3 signaling pathway. Inhibition of STAT3 by Galiellalactone disrupts downstream events associated with LIF signaling, demonstrating its potential to act as a direct inhibitor of LIF by modulating the JAK/STAT3-mediated pathway. | ||||||
Cryptotanshinone | 35825-57-1 | sc-280649 | 10 mg | $119.00 | 1 | |
Cryptotanshinone, a STAT3 inhibitor, directly influences LIF by targeting the JAK/STAT3 signaling pathway. Inhibition of STAT3 by Cryptotanshinone disrupts downstream events associated with LIF signaling, demonstrating its potential to act as a direct inhibitor of LIF by modulating the JAK/STAT3-mediated pathway. | ||||||
Stat3 Inhibitor III, WP1066 | 857064-38-1 | sc-203282 | 10 mg | $132.00 | 72 | |
WP1066, a JAK2/STAT3 inhibitor, directly modulates LIF by affecting the JAK/STAT signaling pathway. Inhibition of JAK2 and STAT3 by WP1066 disrupts downstream events associated with LIF signaling, showcasing its potential to act as a direct inhibitor of LIF by interfering with the JAK/STAT-mediated pathway. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib, a JAK1/2 inhibitor, directly influences LIF by targeting the JAK/STAT signaling pathway. Inhibition of JAK1 and JAK2 by Ruxolitinib disrupts downstream events associated with LIF signaling, demonstrating its potential to act as a direct inhibitor of LIF by modulating the JAK/STAT-mediated pathway. | ||||||